EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion

Adrian Robert Hunt, Yohei Hashimoto, Louise O'Toole, Theodorus Leonardus Ponsioen, Nandor Jaross, Samantha Fraser-Bell, Pavol Kusenda, Socorro Alforja, Daniel Barthelmes, Mark C Gillies, Fight Retinal Blindness! Investigators

British Journal of Ophthalmology · 13.05.2026 · bjo-2025-328709

DOI: 10.1136/bjo-2025-328709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Ophthalmology, online erschienen am 13.05.2026. Verfasst von Adrian Robert Hunt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia adrianhunt@eyesurgeonsmiranda.com.au. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australia, Royal Australian NZ College of Ophthalmologists Eye Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims To identify predictors of continued discontinuation of vascular endothelial growth factor (VEGF) inhibitors for retinal vein occlusion (RVO) after it has been suspended.

Methods

Eyes with RVO were identified in the Fight Retinal Blindness! registry that suspended VEGF inhibitors for ≥180 days when visual acuity (VA) was ≥35 letters, from 1 December 2011–2021. The primary outcome was not resuming therapy through 24 months which defined success.

Results

Half (186/362 (51%)) of the eligible 6-month suspensions successfully continued through 24 months. Successful cessation attempts began earlier (9 vs 14 months; p=0.001), after greater VA improvement (mean, +12.6 vs +8.5 letters; p=0.01) following more injections in the first 6 months (median, 5 vs 4; p

Schlagwörter

Stichwörter der Autor:innen

MaculaVascular Endothelial Growth Factor

Autor:innen und Institutionen

  • Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia adrianhunt@eyesurgeonsmiranda.com.au.
  • Save Sight Institute, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia.
  • Mater Private Hospital, Dublin, Leinster, Ireland.
  • Ophthalmology, Isala, Zwolle, The Netherlands.
  • Australian Eye Specialists, Wyndham, New South Wales, Australia.
  • Sydney Retina Clinic, Sydney, New South Wales, Australia.

Förderung

  • National Health and Medical Research Council, Australia
  • Royal Australian NZ College of Ophthalmologists Eye Foundation

Zitieren

APA

Hunt, A. R., Hashimoto, Y., O'Toole, L., Ponsioen, T. L., Jaross, N., Fraser-Bell, S., Kusenda, P., Alforja, S., Barthelmes, D., Gillies, M. C., & Fight Retinal Blindness! Investigators (2026). Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion. British Journal of Ophthalmology, bjo-2025-328709. https://doi.org/10.1136/bjo-2025-328709

Vancouver

Hunt AR, Hashimoto Y, O'Toole L, Ponsioen TL, Jaross N, Fraser-Bell S, et al. Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion. British Journal of Ophthalmology. 2026:bjo-2025-328709. doi:10.1136/bjo-2025-328709

BibTeX
@article{Hunt2026,
  author = {Hunt, Adrian Robert and Hashimoto, Yohei and O'Toole, Louise and Ponsioen, Theodorus Leonardus and Jaross, Nandor and Fraser-Bell, Samantha and Kusenda, Pavol and Alforja, Socorro and Barthelmes, Daniel and Gillies, Mark C and Fight Retinal Blindness! Investigators, Fight Retinal Blindness! Investigators},
  title = {Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion},
  journal = {British Journal of Ophthalmology},
  year = {2026},
  pages = {bjo--2025--328709},
  doi = {10.1136/bjo-2025-328709}
}
Kostenlos starten →